Entero Therapeutics, Inc.

Equities

ENTO

US33749P4081

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:30:00 23/05/2024 BST			5-day change	1st Jan Change
2.82 ^USD	-4.15%		-4.73%	-32.86%

05-20	Entero Therapeutics, Inc.(NasdaqCM:ENTO) added to NASDAQ Composite Index	CI
05-16	First Wave BioPharma, Inc.(NasdaqGM:ENTO) dropped from NASDAQ Composite Index	CI

AzurRx BioPharma, Inc. Appoints Gregory Oakes to the Board of Directors, Effective April 13, 2020

April 09, 2020 at 04:30 pm

AzurRx BioPharma, Inc. announced the appointment of Gregory Oakes to the Board of Directors effective April 13, 2020. Mr. Oakes brings to the AzurRx Board over 25 years of pharmaceutical industry and leadership experience. He currently serves as Corporate Vice President – Global integration Lead for Otezla at Amgen.

Latest news about Entero Therapeutics, Inc.

Entero Therapeutics, Inc.(NasdaqCM:ENTO) added to NASDAQ Composite Index	05-19	CI
First Wave BioPharma, Inc.(NasdaqGM:ENTO) dropped from NASDAQ Composite Index	05-15	CI
First Wave BioPharma, Inc. announced a financing transaction	05-09	CI
First Wave BioPharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-29	CI
Sector Update: Health Care Stocks Retreating Late Afternoon	03-14	MT
Sector Update: Health Care	03-14	MT
First Wave BioPharma Shares Fall After Acquiring ImmunogenX	03-14	MT
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Thursday Ahead of Inflation Data	03-14	MT
First Wave Biopharma, Inc. Announces Management Changes	03-14	CI
First Wave BioPharma, Inc. completed the acquisition of ImmunogenX, LLC for $57.9 million.	03-12	CI
Top Premarket Gainers	01-03	MT
Wall St ticks up, S&P 500 near all-time closing high	12-27	RE
Sector Update: Health Care Stocks Gain Late Afternoon	12-27	MT
First Wave BioPharma Investors Exercise Warrants at Reduced Price -- Shares Up	12-27	MT
Wall St wavers as S&P 500 hovers near all-time closing high	12-27	RE
Sector Update: Health Care Stocks Higher Wednesday Afternoon	12-27	MT
Sector Update: Health Care	12-27	MT
Wall Street rises, S&P close to all-time high	12-27	RE
Traders Look Ahead to Flat Day After Post-Christmas Rally	12-27	MT
US Stock Market Futures Sluggish Following Holiday Gains	12-27	MT
Top Midday Gainers	12-27	MT
Top Premarket Gainers	12-27	MT
First Wave BioPharma Shares Skyrocket After Selling Prospective Treatment for Inflammatory Bowel Diseases	12-27	MT
First Wave BioPharma, Inc. signed a non-binding term sheet to acquire ImmunogenX, LLC.	12-17	CI
First Wave BioPharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-13	CI

Chart Entero Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Entero Therapeutics, Inc., formerly First Wave BioPharma, Inc., is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. Its programs address unmet needs in GI health and include latiglutenase, a Phase III-ready, oral biotherapeutic designed to aid gluten digestion and potentially reduce symptoms of celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for multiple GI conditions, including gastroparesis, and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency. The Company also intends to develop Niclosamide, an oral small molecule anti-inflammatory inhibitor therapy for the treatment of ulcerative proctitis and ulcerative proctosigmoiditis, and immune checkpoint inhibitor-associated colitis and diarrhea in metastatic cancer patients.

Sector

Biotechnology & Medical Research

Calendar

04/06/2024 - BIO International Convention Conference

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

2.942 USD

Average target price

36 USD

Spread / Average Target

+1,123.66%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
ENTERO THERAPEUTICS, INC.	-32.86%	5.96M
MODERNA, INC.	+64.92%	62.59B
IQVIA HOLDINGS INC.	-1.85%	41.18B
LONZA GROUP AG	+44.76%	40.29B
CELLTRION, INC.	-8.93%	27.9B
ICON PUBLIC LIMITED COMPANY	+13.05%	26.21B
ALNYLAM PHARMACEUTICALS, INC.	-21.96%	19.09B
BIO-TECHNE CORPORATION	+4.21%	13.08B
UNITED THERAPEUTICS CORPORATION	+25.74%	12.26B
MEDPACE HOLDINGS, INC.	+27.42%	12.05B

Other Biotechnology & Medical Research